Equities

Alphatec Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Alphatec Holdings Inc

Actions
  • Price (EUR)11.56
  • Today's Change0.00 / 0.00%
  • Shares traded55.00
  • 1 Year change+8.04%
  • Beta1.0157
Data delayed at least 15 minutes, as of Feb 11 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. The Company is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. The Company's Organic Innovation Machine is focused on developing new approaches that integrate with its expanding Alpha InformatiX (AIX) Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include AIX, positioners, access systems, implants and fixation systems, and biologics. Its AIX product platform comprises its EOS imaging system and VEA alignment mobile application, its SafeOp Neural InformatiX System and its navigation-enabled robotics platform (Valence). It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.

  • Revenue in USD (TTM)728.02m
  • Net income in USD-154.96m
  • Incorporated2005
  • Employees867.00
  • Location
    Alphatec Holdings Inc1950 Camino Via RobleCARLSBAD 92008United StatesUSA
  • Phone+1 (760) 431-9286
  • Fax+1 (302) 636-5454
  • Websitehttps://atecspine.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.